Stay updated on Pembrolizumab in Pancreatic Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Pancreatic Cancer Clinical Trial page.

Latest updates to the Pembrolizumab in Pancreatic Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedRevision updated to v3.6.5, indicating a small system update.SummaryDifference0.0%

- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe revision label on the page was updated from Revision: v3.6.3 to Revision: v3.6.4, indicating a new build. This change does not modify visible content or functionality for users on the study details page.SummaryDifference0.0%

- Check53 days agoChange DetectedRevision number updated from v3.6.2 to v3.6.3, indicating a small software/formatting update rather than a change to the study details or user-facing content. No substantive content changes are indicated.SummaryDifference0.0%

- Check60 days agoChange DetectedRevision label updated from v3.6.0 to v3.6.2. This reflects a system/template update, and no study details or related content seem to be affected.SummaryDifference0.0%

- Check74 days agoChange DetectedUpdates to the study record page include the addition of key attribution details (Craig L Slingluff, Jr and University of Virginia) and new navigation/help links (How to Read a Study Record, Common Questions, How to Join a Study). It also shows changes to status verification labels (Last verified, Last known status was) and a new revision tag (Revision: v3.6.0).SummaryDifference1%

- Check81 days agoChange DetectedRevision updated from v3.5.4 to v3.5.5, signaling a small update to the page. The change appears to be a version bump without visible content edits.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Pancreatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Pancreatic Cancer Clinical Trial page.